Zhongchao Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Weiguang Yang
- Full Time Employees
- 111
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- Nanxi Creative Center Shanghai People's Republic of China 200040
- IPO Date
- Feb 25, 2020
- CIK
- 0001785566
- Website
- izcmd.com
- Similar Companies
- Business
- Zhongchao Inc. (NASDAQ: ZCMD) provides healthcare information, education, and training services to healthcare professionals under the MDMOOC brand, as well as patient management and pharmaceutical services in the People's Republic of China. The company operates through two primary segments: MDMOOC services, which deliver online and onsite health information, healthcare education programs, and training products including clinical practice training, open classes on popular medical topics, interactive case studies, academic conferences and workshops, continuing education courses, and articles and short videos with educational healthcare content; and sales of patented drugs, alongside patient management services in the tumor and rare diseases field, internet healthcare services, and pharmaceutical services through an online information platform. These offerings are accessible via the MDMOOC online platform encompassing the MDMOOC mobile app, MOOC Medical WeChat subscription account, and MDMOOC website, with patient management provided through the Zhongxun brand IT system, WeChat mini programs, and Zhongxin Health WeChat mini program. Zhongchao serves enterprises and non-profit organizations such as medical associations, medical institutions, medical journals, medical foundations, and hospitals, in addition to healthcare professionals including nurses, doctors, and other workers. Founded in 2012 and headquartered at Room 2504, OOCL Tower, 841 Yan'an Middle Road, Jing'an District, Shanghai, China, the company primarily targets the healthcare sector in China, with a focus on bridging medical education and patient care through digital platforms. Recent developments include the renewal of a service agreement with Beijing Public Health Foundation in 2023 to support sustainable cancer patient treatments, reducing financial burdens through medication assistance programs that have served over 7,000 systemic lupus erythematosus patients and more than 10,000 breast cancer patients; strategic partnerships such as with Ximalaya for audio cancer education courses, Johnson & Johnson (China), and introductions of Indian anti-influenza and generic drugs from Natco Pharma Limited; launches of a PRO-based disease management model for lung cancer, a health education intelligent content production platform, medication management assistance mini programs, and a SID liver cancer comprehensive physician education platform; and integration of ChatGPT into the MDMOOC platform and patient services to enhance clinical decision-making and treatment efficiency. In 2025, Zhongchao filed and received effectiveness for Form F-3 shelf registration statements and an S-8 for employee securities, alongside granting 5 million restricted shares to CEO Weiguang Yang under the 2025 Equity Incentive Plan, while receiving a Nasdaq minimum bid price deficiency notice in November 2025 granting until May 2026 for compliance. The company maintains subsidiaries like Zhongchao Education Technology (Beijing) Co., Ltd. and consolidates operations of Shanghai Zhongxin Medical Technology Co., Ltd. through contractual arrangements.
Zhongchao Inc. Announces Pricing of $5 Million Best Efforts Public Offering
Zhongchao Inc. Announces Pricing of $5 Million Best Efforts Public Offering
Reviewing Standard BioTools (NASDAQ:LAB) & Zhongchao (NASDAQ:ZCMD)
Zhongchao Inc. (NASDAQ:ZCMD) Sees Large Decline in Short Interest
Zhongchao (NASDAQ:ZCMD) & Precipio (NASDAQ:PRPO) Financial Review
Zhongchao Inc. Announces 1-for-8 Share Consolidation
Zhongchao Inc. (NASDAQ:ZCMD) Short Interest Up 610.1% in February
Financial Comparison: 10x Genomics (NASDAQ:TXG) vs. Zhongchao (NASDAQ:ZCMD)
Zhongchao Inc. (NASDAQ:ZCMD) Sees Significant Increase in Short Interest
Zhongchao (NASDAQ:ZCMD) vs. Pulmonx (NASDAQ:LUNG) Head to Head Review
Zhongchao (NASDAQ:ZCMD) versus Zepp Health (NYSE:ZEPP) Critical Contrast
Healthcare Triangle (NASDAQ:HCTI) and Zhongchao (NASDAQ:ZCMD) Head-To-Head Contrast
Why Is Zhongchao (ZCMD) Stock Up 52% Today?
Why Is Zhongchao (ZCMD) Stock Up 103% Today?
Why Is Zhongchao (ZCMD) Stock Up 40% Today?
Zhongchao Inc. Announces Successful Medication Assistance Services for Over 7,000 SLE Patients with Approximately 130,000 Units of Medications
Why Is Zhongchao (ZCMD) Stock Up 15% Today?
Zhongchao Inc. Announces 1-for-10 Share Consolidation
Zhongchao Inc. Collaborates with a Public Health Foundation to Support Sustainable and Effective Cancer Treatments
Zhongchao Inc. Launches Breast Cancer Follow-up Visit and Health Management Patient Guide Program on Breast Cancer Awareness Day